Mayo, 2bPrecise Join to Develop Genomics-Based CDS Tools
The Mayo Clinic will work with 2bPrecise, a precision medicine company, to develop and research a genomics-based care protocols approach to providing decision support at the point of care.
The well-known delivery system has signed a license agreement with 2bPrecise, a Pittsburgh-based company that offers an EHR-agnostic cloud-based precision medicine platform that harmonizes genomic data with research knowledge and clinical information.
The partners will use the 2bPrecise platform and combine it with Mayo Clinic’s knowledge and electronic phenotyping algorithms to further develop clinical protocols, which will be used to further develop the capabilities of the platform.
Initial work will be used to apply research to measure outcomes in patients who have cardiovascular genetic disease.
The two organizations will begin their collaboration by bringing a Mayo Clinic algorithm for familial hypercholesterolemia into the 2bPrecise platform to derive insights from combined clinical and genomic research data. The collaboration aims to aid clinical researchers with the ability to test and validate new protocols based on clinical-genomic insights, with the ultimate goal of making these protocols available for optimized decision-making at the point of care.
The 2bPrecise platform harmonizes clinical and genomic information to extract patient-specific insights and present them in an actionable way to the clinician, within their current EHR workflow, overlaying knowledge sources to guide and enable clinical genomics at the point of care.